When was Affera founded?

Affera was founded in 2014 and raised its 1st funding round 7 years after it was founded.

Where is Affera located?

Affera is headquartered in Boston, United States. It is registered at Watertown, Massachusetts.

How many employees does Affera have?

As of Jul 31, 2026, the latest employee count at Affera is 14.

Is Affera a funded company?

Affera is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jan 2021.

When was the latest funding round of Affera?

Affera's latest funding was a $***** Seed round on Jan 2021, with participation from 1 investor. Its primary sector is Cardiac and Vascular Disorders. In United States, the Cardiac and Vascular Disorders sector has seen $1.1B in funding in 2026 to date.

Where does Affera rank among its competitors?

Affera ranks 6th amongst 19 active competitors, of which 12 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Pulsecare Medical Technology, which secured $14M in Nov, 2025.

Who are the top competitors of Affera?

Affera's top competitors include Kardium, Galvanize and Field Medical. Among them, Pulsecare Medical Technology secured the most recent funding round in November, 2025.

Affera - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of devices to treat heart rhythm disorders. The company is developing a comprehensive integrated platform to efficiently deliver durable therapy for a broad set of cardiac arrhythmia patients. The company's products inlcude SpherePVI and Sphere9 catheters.

Website: affera.com
Registered Address: Watertown, Massachusetts

Key Metrics

Founded Year

2014

Location

Boston, United States

Stage

Acquired

Latest Funding Round

Seed, Jan 2021, $*****

Investors

Innogest Capital & 5 more

Ranked

6^th among 19 active competitors

Employee Count

14 as on Jul 31, 2026

Similar Companies

Kardium & 17 more

Exit Details

Acquired by Medtronic (Jan 10, 2022)

View Affera's full profile

Affera is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Affera, Inc. CIN: 472401161 , United States, Active	Dec 26, 999	-	30 (As on Dec 31, 2021)	-

Affera got acquired by Medtronic on Jan 10, 2022.

Click here to take a look at Affera's acquisition in detail

Affera has raised funding over 1 round. Its latest funding round was a Seed round on Jan 2021 for $*****. 1 investor participated in its latest round. Affera has 6 institutional investors.

Here is the list of recent funding rounds of Affera:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 2021	4434156	Seed	8628752	1473043	4768067	8942984

Access funding benchmarks and valuations. Sign up today!

View details of Affera's funding rounds and investors

The founders of Affera is Doron Harlev.

Here are the details of Affera's key team members:

Doron Harlev: Founder & CEO of Affera.

View details of Affera's Founder profiles and Board Members

Affera's employee count trend

Affera has 14 employees as of Jul 26. Here is Affera's employee count trend over the years:

Uncover Affera's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Affera include Kardium, Galvanize and Field Medical. Here is the list of Top 10 competitors of Affera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Kardium 2007, Burnaby (Canada), Series C	Developer of ablation device for atrial fibrillation	$471M	Fidelity Investments, T. Rowe Price & 10 others	65/100
2nd	Galvanize 2020, San Carlos (United States), Series C	Developer of pulsed electric field systems for various medical indications	$210M	Fidelity Investments, Sofinnova Partners ... & 11 others	58/100
3rd	Field Medical 2022, Encinitas (United States), Series B	Developer of device for the treatment of heart arrhythmia conditions	$89M	BioStar Capital, Cue Growth Partners	56/100
4th	Pulse Biosciences 2014, Burlingame (United States), Acquired	Developer of a platform technology called Nano-Pulse Electro-Signaling	$8M	MDB Capital, Sea Purity Investments & 1 others	50/100
5th	Pulsecare Medical Technology 2021, Shenzhen (China), Series A	Developer of medical device solutions for heart and vascular care	$14M	Oriza Holdings, Loayal Valley Capital & 3 others	50/100
6th	Affera 2014, Boston (United States), Acquired	Developer of devices to treat heart rhythm disorders	-	Bain Capital Life Sciences, BAMCAP & 4 others	47/100
7th	Argá Medtech 2020, Epalinges (Switzerland), Series B	Developer of medical devices for treating cardiac arrhythmias	$58.5M	Advent Life Sciences, Earlybird & 1 others	45/100
8th	EnChannel Medical 2020, Ladera Ranch (United States), Series B	Developer of medical device for cardiac disorders	$110M	LAV, DragonBall Capital & 2 others	42/100
9th	Farapulse 2014, Menlo Park (United States), Series C	Advanced cardiac ablation solutions for atrial fibrillation treatment	$36.3M	F-Prime Capital, Boston Scientific & 3 others	42/100
10th	AtriAN 2017, Galway (Ireland), Seed	Developing the device that targets to atrial fibrillation	$2.56M	Western Development Commission, Mayo Clinic Ventures ... & 4 others	34/100